glp 1 agonisté Mechanisms of action of GLP-1RA A Closer Look at the
Description
Whats Fueling Market Momentum

Breitzig: Lan Kong: Erika F

doi: 10.2337/diabetes.54.2.482

Although these trials primarily enrolled individuals with relatively low DKD risk and were not designed to evaluate kidney outcomes specifically, exploratory analyses consistently indicated slower kidney disease progression across diverse eGFR and albuminuria levels [39-44]

Ongoing trials with incretin-based therapies that investigate potential renoprotective mechanisms

Certain medications, like Wegovy, were specifically made and approved as weight loss drugs
